explore -WSS

explore

author：fashion 2025-08-12 09:11:34 - browse：39511

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Wikipedia

WSS

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

STAT wants to know your pick for a great summer read or listen

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Skip the lead apron during X

Beware reading your test results before your doctor does

Being 'nonadherent' patient made me a more empathetic doctor

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Oak Street deal isn't the answer to health care's woes

Alkermes shareholders re

STAT wants to know your pick for a great summer read or listen

Medicare proposal to cover medical devices draws a mixed reaction

Being 'nonadherent' patient made me a more empathetic doctor

Virginia high school admissions case could be legal follow

Skip the lead apron during X

What does generative AI mean for health care? We asked experts

The wait for US passports is creating travel purgatory and snarling summer plans

leisure time

Dexcom's push to bring CGM to type 2 diabetes patients

Free medical tuition alone isn't enough to close gaps in primary care

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

As H5N1 spreads in cows, experts warn against drinking raw milk

CVS is willing to dump 10% of its Medicare Advantage members

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

hotspot

Wikipedia

entertainment

explore